Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04093336|
Recruitment Status : Recruiting
First Posted : September 18, 2019
Last Update Posted : October 28, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2. Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of MSCs. Potential subjects must be screened and consented before enrolled.
The primary objective of this study is to determine the effects of early intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or MSCs used in the following section) for patients with acute ischemic stroke. Eligible patients will receive a single dose of MSCs or placebo within 24 hours after stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change in neurological symptoms and quality of life). Assessments will occur during transplantation and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.
|Condition or disease||Intervention/treatment||Phase|
|Infarction, Middle Cerebral Artery Infarction, Anterior Cerebral Artery Cerebral Infarction Stroke, Ischemic Acute Stroke Brain Infarction Infarction, PCA Infarction, Posterior Circulation, Brain||Biological: human umbilical cord mesenchymal stem cells Biological: Placebo Other: standardized treatment||Phase 1 Phase 2|
In Phase 1 study, the eligible patients of acute cerebral infarction within 7 days after onset will be randomized to MSCs group or control group and receive intravenous MSCs 2 x 10^6/kg or placebo as a single dose, respectively. Each group will enroll 10 patients and patients will be followed for 2 years to observe the adverse events and evaluate the safety of MSCs for acute ischemic stroke patients.
The safety and preliminary effectiveness of MSCs in the treatment of acute cerebral infarction will be summarized after all patients of Phase 1 study were followed for 3 months post infusion, and the report will be submit to the academic committee and the ethics committee to evaluate before approval to begin the Phase 2 study.
In Phase 2 study, 100 patients with acute infarction within 24 hours after onset will be enrolled and randomized to MSCs group or control group. Patients will have baseline laboratory examinations and cerebral image (MRI or CTP). Enrolled patients will receive intravenous infusion of 2*10^6/kg MSCs or placebo for a single dose and follow for 24 months to assess the adverse events, neurological functional recovery and quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||placebo controlled, randomized, double blinded|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients|
|Actual Study Start Date :||January 13, 2019|
|Estimated Primary Completion Date :||April 30, 2024|
|Estimated Study Completion Date :||August 31, 2024|
Active Comparator: MSCs group
The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.
Biological: human umbilical cord mesenchymal stem cells
The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
Other: standardized treatment
Placebo Comparator: control group
The people in this group will receive placebo and standardized treatment of acute ischemic stroke.
Other: standardized treatment
- adverse events [ Time Frame: 24 months post transplantation ]include tumorigenesis, death, pulmonary embolism, allergy, newly cerebrovascular events and other adverse events to evaluate the safety of MSCs for acute ischemic stroke patients
- the National Institutes of Health Stroke Scale (NIHSS) of 3 months [ Time Frame: 3 months post transplantation ]The NIHSS neurologic examination includes 15 individual elements that measure motor and sensory function, language and speech production, vision, level of consciousness and attention, and neglect. The scores of each element are summed (range from 0 to 42) to evaluate the severity of neurological deficits. The more higher score means the more severe neurological dysfunction.
- the Barthel index (BI) of 3 months [ Time Frame: 3 months post transplantation ]The BI (range from 0 to 100) are used to assess the difference of activities of daily living between two groups. the score ≤40 means severe dependence， score 41~60 means moderate dependence, score 61~99 means mild dependence and score 100 means independence.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Acute ischemic stroke;
- Age 18~80y;
- 4≤NIHSS score≤18（including limb score≥2）and modified Rankin scale 0-1 before this cerebral ischemic stroke;
- patients and their families understand and will cooperate within the whole process of study, and sign informed consent;
- any of following items：①acute cerebral infarction confirmed by cerebral CT perfusion or non-contrast computed tomographic scan < 7 days after onset or ②acute cerebral infarction confirmed by cerebral MR image < 7 days after onset
- accompanied by hematological disease, severe infection, liver dysfunction (ALT>3*ULN), kidney dysfunction (Scr >2*ULN), cardiac dysfunction (NYHA grade III or IV);
- Disturbance of consciousness, mental illness, cognitive impairment and other diseases that may affect informed consent and evaluation of study.
- Malignancy history or found to associate cancer after this stroke
- Pregnant or lactating women, or women have fertility requirements within 2 years;
- Accompanied by immunodeficiency diseases or autoimmune diseases;
- Life expectancy is less than 2 years;
- Participated in other clinical trial within 6 months;
- Patients received Chinese traditional medicine after onset of this stroke;
- Patients with allergic predisposition;
- Mental implantation or other reasons cannot tolerate magnetic resonance imaging;
- Cannot follow up regularly or unwilling to sign informed consent;
- Other situations not suitable for enrollment judged by the researchers;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04093336
|Contact: Gang Li, Doctorfirstname.lastname@example.org|
|Contact: Lian Zuo, Doctoremail@example.com|
|Shanghai, Shanghai, China, 200123|
|Contact: Gang Li, Doctor 0086-021-38804518-22106|
|Principal Investigator:||Gang Li, Doctor||Shanghai East Hospital|
|Responsible Party:||Shanghai East Hospital|
|Other Study ID Numbers:||
|First Posted:||September 18, 2019 Key Record Dates|
|Last Update Posted:||October 28, 2021|
|Last Verified:||October 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Acute cerebral infarction ,Mesenchymal Stem Cells,prognosis
Infarction, Middle Cerebral Artery
Infarction, Anterior Cerebral Artery
Infarction, Posterior Cerebral Artery
Central Nervous System Diseases
Nervous System Diseases
Cerebral Arterial Diseases
Intracranial Arterial Diseases